ClinicalTrials.gov
ClinicalTrials.gov Menu

Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects (Salmon-Basel)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01957293
Recruitment Status : Completed
First Posted : October 8, 2013
Last Update Posted : December 16, 2014
Sponsor:
Collaborator:
Clinical Trial Unit, University Hospital Basel, Switzerland
Information provided by (Responsible Party):
Prof. Dominique de Quervain, MD, University of Basel

Brief Summary:
Aim is to investigate the effect of beta2 adrenergic stimulant salbutamol on emotional and cognitive functions in healthy humans.

Condition or disease Intervention/treatment Phase
Memory Functions Drug: Salbutamol Drug: Placebo Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
Official Title: Influence of Salbutamol on Emotional and Cognitive Functions in Healthy Subjects
Study Start Date : October 2013
Actual Primary Completion Date : January 2014
Actual Study Completion Date : February 2014

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Memory

Arm Intervention/treatment
Experimental: Salbutamol Drug: Salbutamol
single oral administration, 4 mg

Placebo Comparator: Sugar Syrup Drug: Placebo
single oral administration




Primary Outcome Measures :
  1. Change of emotional memory functions under Salbutamol [ Time Frame: two testing days within 10 days ]
    memory tests

  2. Change of episodic memory functions under Salbutamol [ Time Frame: two testing days within10 days ]
    memory tests


Secondary Outcome Measures :
  1. Change of emotional state under salbutamol [ Time Frame: Two testing days within 10 days ]
    questionnaires

  2. change of attention functions under salbutamol [ Time Frame: two testing days within 10 days ]
    attention tests



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

Healthy, male and female, aged between 18 and 40, BMI be-tween 19 and 27 kg/m2, normotensive (BP between 90/60 mmHg and 140/90 mmHg), native or fluent German-speaking, caucasian (European ancestry), able and willing to give written informed consent and comply with the requirements of the study protocol, willing to donate saliva sample for DNA-analysis -

Exclusion Criteria:

Acute or chronic psychiatric or somatic disorder, tachycardia at rest (> 100 bpm), known hypersensitivity to salbutamol, pathological ECG, pregnancy, breast-feeding, long-term medication within last 3 months (oral contraceptives are disregarded) smoking (>3 cigarettes per day), concurrent participation in another study, participation in one of our previous studies using the same memory tests, inability to read and understand the participant's information. -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01957293


Locations
Switzerland
University of Basel, Division of Cognitive neuroscience
Basel, Switzerland, 4055
Sponsors and Collaborators
Prof. Dominique de Quervain, MD
Clinical Trial Unit, University Hospital Basel, Switzerland
Investigators
Study Director: Dominique de Quervain, Prof. MD University of Basel

Responsible Party: Prof. Dominique de Quervain, MD, Director of teh Division of Cognitive Neuroscience, University of Basel
ClinicalTrials.gov Identifier: NCT01957293     History of Changes
Other Study ID Numbers: 2013DR2134
First Posted: October 8, 2013    Key Record Dates
Last Update Posted: December 16, 2014
Last Verified: February 2014

Additional relevant MeSH terms:
Albuterol
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Tocolytic Agents
Reproductive Control Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action